PHAT · Phathom Pharmaceuticals, Inc.
$8.60
-0.72 (-7.73%)
At close · Aug 20
Market Cap
$754.00M
Shares
80.90M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.60
Open$9.25
Day$8.40–9.30
52W close$8.23–18.08
Avg vol 30d1.5M
Short int13.3M · 16.5% float · 8.7d
Short vol58%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
−17%
below
RSI (14)
38
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−26%
trailing
6-month return
−32%
trailing
YTD return
−48%
this year
Relative strength
−43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.47% of float · ▲ +9.9% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+217%
Y/Y
Gross margin
87%
expanding
EPS growth
+43%
Y/Y
Free cash flow
$-167.0M
Balance sheet
$79.1M
net debt
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Gross margin
· FY 2026
Initiated
80%
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Full year revenue
· full year 2025
$170M – $175M
Non-GAAP operating expenses
· full year 2025
$280M – $290M
Gross to net
· fourth quarter
55% – 60%
Non-GAAP operating expenses (CashOpex)
· fourth quarter 2025
up to $55M
Operating expenses excluding stock-based compensation
· fourth quarter
up to $55M
Guided vs delivered
· last 1 settled
Full year revenue
full year 2025
guided $170M – $175M
$175.11M
Beat +1.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
−17%
Bearish
RSI (14)
38
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.47% of float · ▲ +9.9% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $8
Now $9 · 4%
Range high $18
vs 200-day avg -30%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Covered prescriptions filled during the second quarter | 209,000 | the second quarter | — |
| Non-GAAP adjusted net loss non-GAAP | $0.1M | the second quarter 2026 | — |
|
|
|||
| Non-GAAP operating expenses, excluding stock-based compensation non-GAAP | $56.4M | the second quarter 2026 | — |
| Total VOQUEZNA prescriptions filled during the second quarter | 325,000 | the second quarter | — |
| total VOQUEZNA prescriptions filled to date | 1.7M | as of July 17, 2026 | — |
| Covered prescriptions year-over-year growth | 91% | first quarter 2026 | — |
| Total VOQUEZNA prescriptions filled in the first quarter | 268,000 | first quarter 2026 | — |
| Covered prescriptions growth | 21% | the fourth quarter | — |
| Net cash usage | 5.2M | the fourth quarter | — |
| Non-GAAP operating expenses non-GAAP | 283.8M | the full year | — |
| VOQUEZNA total prescriptions filled | 1.1M | as of February 13, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PHAT
this stock
Phathom Pharmaceuticals, Inc.
|
$754.00M | -48.2% | +216.9% | — | 16.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PHAT | -6.3% | -25.9% | -31.5% | -1.7% | -48.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -4.4% | -29.2% | -42.7% | -3.8% | -60.0% |
Key facts
CIK
1783183
CUSIP
71722W107
13F (30d)
155 filings
151 filers
Visit website
Investor relations